<DOC>
	<DOCNO>NCT00298324</DOCNO>
	<brief_summary>The purpose study determine whether response treatment extensive chronic Graft versus Host Disease ( cGvHD ) improve addition myfortic alongside cyclosporine A prednisone , compare reference treatment cyclosporine A prednisone alone .</brief_summary>
	<brief_title>Myfortic - Treatment Extensive cGvHD</brief_title>
	<detailed_description>This clinical trial European , multi-center , randomize , double blind placebo-controlled trial compare CsA+PDN+MPA versus reference treatment CsA+PDN alone + placebo , patient extensive chronic GvHD . Randomization stratify accord : - Platelet number ( low versus high risk ) - Source transplantable cell ( marrow versus PBSC versus cord blood ) Patients progression 6 week post randomization ( progression define primary failure ) evaluate remission ( complete partial ) 3 , 6 , 9 , &amp; 12 month post randomization</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Age 18 60 Any primary diagnosis require treatment hematopoietic stem cell transplantation Recipient single allogeneic stem cell transplant ( bone marrow peripheral blood stem cell , cord blood ) minimum 80 day ago Received graft relate unrelated donor Conditioning regimen : Myeloablative nonmyeloablative Patients suffer first episode extensive chronic GvHD , without recurrent disease The diagnosis chronic GvHD require follow : Distinction acute GvHD Presence least one diagnostic clinical sign chronic GvHD presence least one distinctive sign confirm pertinent biopsy relevant diagnostic test Exclusion possible diagnosis Receiving standard prophylaxis regimen acute GvHD : CsA plus methotrexate , CSA+MMF NMA , Tcell deplete transplant Patient give write informed consent prior randomization Patient age less 18 year 60 year . GvHD prophylaxis tacrolimus plus methotrexate Delayed onset acute GvHD follow NMA DLI Second allogeneic stem cell transplant Not first episode chronic GvHD need systemic immunosuppressive therapy . Limited chronic GvHD ( Seattle criterion , see Appendix 1 ) Uncontrolled systemic infection opinion investigator associate increase risk patient 's death within 1 week randomization In opinion investigator , patient significant medical psychosocial problem unstable disease status Pregnant lactating female Known hypersensitivity mycophenolic acid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>GvHD</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>extensive</keyword>
	<keyword>myfortic</keyword>
</DOC>